Dr Sandy Primrose, Chairman
Dr. Sandy Primrose is a non-executive director (NXD) and Chairman of the Board of Directors of Fios Genomics. He is currently NXD Chairman at Arrayjet Ltd and Cellexus Limited and he represents The London Technology Fund and Esperante Ventures. He is also on the Board of Immune Targeting Systems Ltd. Sandy is the senior partner at Business and Technology Management, a biotechnology and healthcare consultancy practice. Previously, Sandy was an academic at Warwick University and then held posts as Senior Director of Drug Development at Searle Research and Development and then managed the Life Science business of Amersham International (now part of GE). After that he held senior management positions in a number of early stage companies as well as serving on the board of the Microbiological Research Authority (a Special Health Authority) and then the Health Protection Agency.
Dr Ian Campbell, CEO
Ian is an experienced entrepreneur in life sciences and the diagnostics sector. Previously he served as Chief Executive of Molecular Vision, an Imperial College spin-out company, developing a disposable, quantitative Point–of-Care diagnostic platform, which was acquired by Abingdon Health in 2012. Most recently Ian has served as Commercial Director with Bespak Europe Ltd. Ian has a strong scientific background, gaining his PhD at the University of Glasgow.
Dr Nick Miller-Jones, Technical Director
Nick led the Life Sciences Division of Scientific Generics Ltd, one of the UK’s leading technology consultancy companies and has over 20 years experience in the biotech, life sciences and healthcare industries. He has worked in a number of disciplines including lab-based point-of-care assay development, market analysis and positioning, market entry strategy, identification of companies for acquisition and due diligence on life science companies on behalf of investors.
Tristan Sillars, Finance and Operations Director
A Chartered Accountant, Tristan has concentrated on interim and part-time Head of Finance roles for the last five years as well as raising money for SMEs, aided by his corporate finance and financial modelling expertise. Previously, Tristan worked for KPMG Transaction Services, covering a wide range of deal activity across the UK.
Dr Elisabeth Parker, Non-executive Director
Elisabeth represents Cancer Research Technology and is a Business Development Executive at Cancer Research Technology (CRT) from which Urosens’ key IP is licensed. At CRT Elisabeth is responsible for commercialisation and development of IP arising from Cancer Research UK funded research. Prior to joining CRT, Elisabeth was the Research Manager at KS Biomedix, a UK quoted biopharmaceutical company that developed diagnostic and therapeutic antibodies.
Dean Slagel, Non-executive Director
Dean represents Esperante Ventures. With an MBA from the ENPC School of Management in Paris, Dean brings 12 years of pharmaceutical industry experience. He joined Ferring in 1995, with responsibilities ranging from regional strategic management to licensing and acquisitions and ultimately being appointed Global Business Development Director in 2000, a role he ceased in 2003 to establish Esperante.
Dr Alex Buchan, Observer
Alex represents NorthStar Ventures. He joined Northstar in September 2004 following a series of senior commercial roles in the biotechnology sector: Cybersense, Compugen, SDI Europe, EnSys Europe and Archaeus. Alex completed a PhD in Microbiology before spending 3 years in London as a stockbroker for UBS Phillips and Drew